text: Dendrimers have the potential to completely change the pharmacokinetic and pharmacodynamic (PK/PD) profiles of a drug. As carriers, the PK/PD is no longer determined by the drug itself but by the dendrimer’s localization, drug release, and dendrimer excretion. ADME properties are very highly tunable by varying dendrimer size, structure, and surface characteristics. While G9 dendrimers biodistribute very heavily to the liver and spleen, G6 dendrimers tend to biodistribute more broadly. As molecular weight increases, urinary clearance and plasma clearance decrease while terminal half-life increases.